Research Summary

Dr. Hala Borno is faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. She cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, GU committee for NRG oncology, and Health Disparities Committee for Alliance for Clinical Trials in Oncology.

Dr. Borno's research program consists of prostate cancer therapeutic development and cancer disparities. She serves as medical oncology co-chair for phase III clinical trials and is the principal investigator for clinical trials conducted at HDFCCC in advanced prostate cancer. Dr. Borno has an extensive research program on the promotion of equity in cancer precision medicine.

She has developed novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials. Dr. Borno used human-centered design to develop Trial LibraryTM, a patient facing clinical trial matching tool. Dr. Borno's research has been featured in peer-reviewed journals such JAMA Oncology, Cancer, and Nature. Her work has been covered by national news outlets such as NPR, Washington Post, CBS News, Bloomberg News, and STAT News.

Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics.

Education

University of North Carolina at Chapel Hill, B.S., 05/2008, Biochemistry
University of North Carolina at Chapel Hill, M.D., 05/2013, Medicine
University of California, San Francisco, Intern, 06/2014, Internal Medicine
University of California, San Francisco, Resident, 06/2016, Internal Medicine

Honors & Awards

  • 2009
    Foreign Language Area Studies Fellowship
  • 2011-2012
    Furlow Fund Global Health Research Fellowship, University of North Carolina at Chapel Hill
  • 2009-2013
    Medical Alumni Loyalty Fund Scholarship
  • 2013
    Arnold P. Gold Foundation
  • 2013
    Daniel T. Young Peace and Social Justice Award
  • 2017-present
    Geriatrics T32 NIH Grant
  • 2017-present
    Inside Out Accelerator Grant from the Clinical Innovation Center

Selected Publications

  1. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS Differential Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer.  View on PubMed
  2. Borno HT, Andemeskel G, Palmer NR Redefining Attribution From Patient to Health System-How the Notion of "Mistrust" Places Blame on Black Patients.  View on PubMed
  3. Stacy Loeb, Rada Mihalcea, Veronica Perez-Rosas, Alex Xu, Jacob Taylor, Nataliya Byrne, Dawn Walter, Marina Ness, Rebecca Robbins, Sylvia Zhang, Trevor Killeen, Divya Natesan, Hala T. Borno Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer.  View on PubMed
  4. Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT Examining reporting and representation of patients with cancer in COVID-19 clinical trials.  View on PubMed
  5. Daniel Kwon, Rohit Vashisht, Hala Borno, Rahul Raj Aggarwal, Eric Jay Small, Atul Butte, Franklin W. Huang Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study.  View on PubMed
  6. Hala Borno, Sylvia Zhang, Scarlett Lin Gomez, Celia Kaplan, Christine Miaskowski, Julian Hong, Dame Idossa, Adina Bailey, Eric Jay Small Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies.  View on PubMed
  7. Ronald C. Chen, Theodore Karrison, Colleen Anne Lawton, William Adrian Hall, Hala Borno, Mihaela Rosu, Ashesh B. Jani, David M. Schuster, Michael J. Seider, Jason A. Efstathiou, Edwin Melencio Posadas, Paul L. Nguyen, Felix Y Feng INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.  View on PubMed
  8. Hala Borno, Patricia Li, Sylvia Zhang, Dame Idossa, Arpita Desai, Tammy J. Rodvelt, Rohit Bose, Vadim S Koshkin, Jonathon Chou, Terence W. Friedlander, Franklin W. Huang, Eric Jay Small, Rahul Raj Aggarwal Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center.  View on PubMed
  9. Barry Tong, Hala Borno, Fern Alagala, Kelly Gordon, Eric Jay Small, Amy M. Lin, Amie Blanco, Mallika Sachdev Dhawan Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.  View on PubMed
  10. Errol J. Philip, Sylvia Zhang, Peggy Tahir, Daniel Kim, Francis Wright, Alexander Bell, Hala T. Borno Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review.  View on PubMed
  11. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW Androgen deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.  View on PubMed
  12. Borno HT, Duffy C, Zhang S, Canchola AJ, Loya Z, Golden T, Oh DL, Odisho AY, Gomez S Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer.  View on PubMed
  13. Borno HT, Idossa D, Gomez SL Policy and Health: Leveraging a Social Determinants of Health Framework to Alleviate the Impact of the COVID-19 Pandemic on Patients With Cancer.  View on PubMed
  14. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.  View on PubMed
  15. Borno HT, Odisho AY, Gunn CM, Pankowska M, Rider JR Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer.  View on PubMed
  16. Hala Borno, Sylvia Zhang, Elena Nieves, Dana Dornsife, Robert G. Johnson, Darcy V. Spicer Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study.  View on PubMed
  17. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA Disparities in PET imaging for prostate cancer at a tertiary academic medical center.  View on PubMed
  18. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Hammer MJ, Kenfield SA, Kober KM, Levine JD, Pozzar R, Rhoads KF, Van Blarigan EL, Van Loon K Stress and Symptom Burden in Oncology Patients During the COVID-19 Pandemic.  View on PubMed
  19. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Laffan A, Levine JD, Pozzar R, Tsai KK, Van Blarigan EL, Van Loon K Oncology patients' perceptions of and experiences with COVID-19.  View on PubMed
  20. Borno HT, Cowan JE, Zhao S, Broering JM, Carroll PR, Ryan CJ Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.  View on PubMed

Go to UCSF Profiles, powered by CTSI